<DOC>
	<DOC>NCT02293629</DOC>
	<brief_summary>This is the first clinical study with the BMS-986147 compound in healthy subjects. The purpose of this study is to guide the dose range and dose frequency for future studies with BMS-986147 and will provide guidelines for selection of a potentially effective dose in patients.</brief_summary>
	<brief_title>A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Healthy men and women, ages 18 to 45 years Subjects must not have clinically significant deviation from normal: medical history, physical examination, ECGs and laboratory evaluations Women of child bearing potential are eligible for enrollment. Women must have a negative pregnancy test Evidence of organ dysfunction Any significant acute or chronic medical illness Inability to: tolerate oral medications, be venipunctured</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Subjects</keyword>
</DOC>